What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?

Thomas Schön, Claudio Umberto Köser, Jim Werngren, Miguel Viveiros, Sophia Georghiou, Gunnar Kahlmeter, Christian Giske, Florian Maurer, Gerard Lina, John Turnidge, Jakko van Ingen, Mateja Jankovic, Delia Goletti, Daniela Maria Cirillo, Miguel Santin, Emmanuelle Cambau

Research output: Contribution to journalComment/debatepeer-review

3 Citations (Scopus)

Abstract

Drug-resistant tuberculosis (TB) is estimated to account for approximately 30% of annual deaths due to antimicrobial resistance (AMR) [ 1 ]. This is mainly due to mortality of approximately 44% caused by multidrug-resistant (MDR) TB (defined by resistance to isoniazid and rifampicin) [ 2 ]. Therefore, accurately diagnosing AMR for TB is crucial not only to select the most effective regimen with the least side effects but also to minimize costs (e.g. the median cost to treat MDR-TB is $6430 compared with $973 for drug-susceptible TB) [ 2 ]. Owing to the slow growth rate of the Mycobacterium tuberculosis complex (MTBC), this is increasingly achieved using genotypic approaches [ 3 ]. However, phenotypic antimicrobial susceptibility testing (pAST) is still needed to correlate the presence of mutations and their phenotypic expression, especially for new anti-TB agents for which resistance mutations are unknown.
Original languageEnglish
Pages (from-to)1453-1455
Number of pages3
JournalClinical Microbiology And Infection
Volume26
Issue number11
DOIs
Publication statusPublished - 1 Nov 2020

Keywords

  • Drug susceptibility testing
  • EUCAST
  • MDR
  • MIC
  • Tuberculosis

Fingerprint

Dive into the research topics of 'What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?'. Together they form a unique fingerprint.

Cite this